Advertisement
CLLS vs SLN
Which Stock Would AI Choose? Cellectis S.A. (CLLS) vs. Silence Therapeutics plc (SLN) Stock Comparison
Key Takeaways
- Both CLLS and SLN are clinical-stage biotech firms focused on gene-editing and RNA interference (RNAi) technologies, respectively, targeting oncology and rare diseases.
- CLLS shows stronger recent momentum with 24% gain over the past month and positive interim data from the cema-cel CAR-T (chimeric antigen receptor T-cell) trial, achieving 58.3% minimal residual disease (MRD) negativity.
- SLN completed enrollment in the Phase 2 SANRECO trial for divesiran in polycythemia vera (PV), with topline data expected in Q3 2026, but experienced leadership changes and a 13-18% monthly decline.
- CLLS has higher trailing twelve-month (TTM) revenue ($79.59M vs. $0.56M) and a larger cash position ($206M), supporting longer runway amid negative earnings.
- Over one year, CLLS returned 196% vs. SLN's 120%, though both lag broader indices year-to-date.
- Market caps are comparable (~$370-440M), with SLN showing higher analyst upside potential (price targets ~$33-75).
Introduction
This stock comparison examines CLLS and SLN, two European biotech companies advancing innovative therapies in immuno-oncology and genetic diseases. Both operate in high-risk, high-reward clinical stages, drawing interest from traders tracking biotech momentum and investors seeking exposure to gene-editing and siRNA (short interfering RNA) platforms. Recent clinical milestones and market volatility make this analysis timely for those evaluating relative performance, sector catalysts, and positioning amid broader biotech sentiment shifts.
CLLS Overview and Recent Performance
Cellectis S.A. (CLLS), headquartered in Paris, France, is a clinical-stage biotech firm pioneering gene-editing technologies for allogeneic CAR-T therapies in immuno-oncology and gene therapy. Its pipeline includes lasme-cel for relapsed/refractory acute lymphoblastic leukemia (ALL), eti-cel for non-Hodgkin lymphoma (NHL), and partnerships like cema-cel with Allogene Therapeutics.
In recent market activity, CLLS gained over 24% in the past month, trading around $4.27 with a 52-week range of $1.33-$5.48. Year-to-date returns stand at 10.67%, outperforming the CAC 40 benchmark. Sentiment has been bolstered by interim data from the ALPHA3 pivotal trial of cema-cel, showing 58.3% MRD negativity at Day 45 versus 16.7% in controls, highlighting the platform's potential in large B-cell lymphoma. Q4 2025 earnings reflected revenue of $10.58M, with cash reserves at $206M supporting ongoing trials. Volatility persists due to clinical risks, but positive futility analysis has driven short-term upside.
SLN Overview and Recent Performance
Silence Therapeutics plc (SLN), based in London, UK, develops siRNA therapeutics to silence disease-causing genes in hematology, cardiovascular, and rare diseases. Key candidates include divesiran (SLN124) for polycythemia vera, zerlasiran (SLN360) for lipoprotein(a)-driven cardiovascular risk, and others like SLN312 for dyslipidemia.
Recent weeks saw SLN fluctuate around $5.96, within a 52-week range of $2.63-$7.91, with a roughly 13-18% monthly dip amid broader European ADR trading. Year-to-date performance is 1.97%, trailing the S&P 500 slightly, though one-year returns reach 120%. Progress includes completing enrollment in the Phase 2 SANRECO trial for divesiran, anticipating topline data in Q3 2026, and additional Phase 1 results showing hematocrit control in PV patients. Q4 2025 revenue was minimal at $25k, with $85M cash and low debt. Leadership transitions, including CEO changes, have introduced uncertainty, tempering sentiment despite high analyst targets.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases top-performing AI trading bots curated from hundreds available on the platform, which collectively trade thousands of tickers across stocks, ETFs, and crypto. Only the most suitable for current market conditions—based on metrics like annualized returns, win rates, and adaptability—earn a spot among the 25 featured trending bots out of 351 total. Performance highlights include annualized returns ranging from +16.77% to +136.62%, win rates of 53-87%, and bots trading 1-25 tickers in volatile sectors like semiconductors and energy. Diverse strategies encompass swing trading, trend following, multi-agent systems, and volatility plays with take-profit/stop-loss corridors (e.g., 3% TP/2% SL). These AI/ML-driven tools offer varied timeframes from 5 to 60 minutes, enabling copy trading without minimum balances for signals. Explore Tickeron’s offerings to align bots with your trading style.
Head-to-Head Comparison
CLLS and SLN share biotech exposure but diverge in models: CLLS leverages TALEN gene-editing for off-the-shelf CAR-T in oncology, while SLN uses siRNA for gene silencing in cardio-hematology. Growth drivers include CLLS's partnership milestones (e.g., Allogene's ALPHA3) versus SLN's SANRECO readout.
Recent momentum favors CLLS (24% monthly gain, YTD +10.67%) over SLN's pullback, with CLLS boasting superior revenue ($79.59M TTM vs. $0.56M) and cash ($206M vs. $85M). Risks are acute: CLLS faces trial failures and higher beta (2.71), SLN executive flux and AstraZeneca's SLN312 halt. Sector-wise, both tap immuno-oncology/rare diseases, but CLLS aligns with CAR-T hype. Sentiment tilts to CLLS on catalysts, though SLN offers higher valuation upside.
Tickeron AI Verdict
Tickeron’s AI currently favors CLLS due to consistent recent trends, superior revenue generation, robust cash position, and fresh cema-cel data signaling clinical momentum. Relative stability and oncology catalysts position it ahead probabilistically, though SLN's siRNA pipeline and enrollment milestones warrant monitoring for potential reversal.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and SLN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 0 FA rating(s) are green whileSLN’s FA Score has 0 green FA rating(s).
- CLLS’s FA Score: 0 green, 5 red.
- SLN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 4 TA indicator(s) are bullish while SLN’s TA Score has 6 bullish TA indicator(s).
- CLLS’s TA Score: 4 bullish, 7 bearish.
- SLN’s TA Score: 6 bullish, 5 bearish.
Price Growth
CLLS (@Biotechnology) experienced а +1.82% price change this week, while SLN (@Biotechnology) price change was -12.48% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.25%. For the same industry, the average monthly price growth was -2.77%, and the average quarterly price growth was +7.50%.
Reported Earning Dates
CLLS is expected to report earnings on Jul 30, 2026.
SLN is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Biotechnology (-2.25% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CLLS | SLN | CLLS / SLN | |
| Capitalization | 421M | 206M | 204% |
| EBITDA | -39.82M | -76.56M | 52% |
| Gain YTD | -19.008 | 0.329 | -5,779% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 68.1M | 839K | 8,117% |
| Total Cash | 186M | 70.1M | 265% |
| Total Debt | 86.5M | 136K | 63,603% |
CLLS | ||
|---|---|---|
OUTLOOK RATING 1..100 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 41 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CLLS | SLN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 81% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 84% | 3 days ago 84% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 77% | 3 days ago 89% |
| TrendMonth ODDS (%) | 3 days ago 87% | 3 days ago 89% |
| Advances ODDS (%) | 4 days ago 78% | 4 days ago 88% |
| Declines ODDS (%) | 10 days ago 88% | 19 days ago 90% |
| BollingerBands ODDS (%) | 5 days ago 79% | 3 days ago 90% |
| Aroon ODDS (%) | 6 days ago 87% | 3 days ago 86% |
Advertisement
CLLS and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLLS has been closely correlated with CMVLF. These tickers have moved in lockstep 82% of the time. This A.I.-generated data suggests there is a high statistical probability that if CLLS jumps, then CMVLF could also see price increases.
| Ticker / NAME | Correlation To CLLS | 1D Price Change % | ||
|---|---|---|---|---|
| CLLS | 100% | -3.69% | ||
| CMVLF - CLLS | 82% Closely correlated | N/A | ||
| SLN - CLLS | 43% Loosely correlated | -14.45% | ||
| MDGL - CLLS | 40% Loosely correlated | -3.00% | ||
| PMVP - CLLS | 38% Loosely correlated | -3.01% | ||
| AXON - CLLS | 36% Loosely correlated | +0.95% | ||
More | ||||
SLN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLN has been loosely correlated with CLLS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SLN jumps, then CLLS could also see price increases.
| Ticker / NAME | Correlation To SLN | 1D Price Change % | ||
|---|---|---|---|---|
| SLN | 100% | -14.45% | ||
| CLLS - SLN | 43% Loosely correlated | -3.69% | ||
| CMVLF - SLN | 38% Loosely correlated | N/A | ||
| TSHA - SLN | 36% Loosely correlated | -5.40% | ||
| VIR - SLN | 33% Poorly correlated | -3.30% | ||
| RCUS - SLN | 32% Poorly correlated | -4.69% | ||
More | ||||